Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALA-CORT vs BETA-2
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.
Beta-2 adrenergic receptor agonist; stimulates adenylate cyclase, increasing c AMP, leading to bronchodilation and inhibition of mast cell mediator release.
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (FDA),Off-label: Atopic dermatitis, psoriasis, contact dermatitis, lichen planus, discoid lupus erythematosus
FDA-approved: Treatment of asthma (acute bronchospasm and prophylaxis), COPD exacerbations,Off-label: Preterm labor tocolysis, hyperkalemia
Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.
2.5 mg via nebulization every 4-6 hours as needed for bronchospasm; or 90 mcg (2 inhalations) via metered-dose inhaler every 4-6 hours.
Terminal elimination half-life: 1–2 hours for hydrocortisone (active component), prolonged in liver disease or with concurrent CYP3A4 inhibitors.
Terminal elimination half-life of 3-6 hours; clinical context: requires frequent dosing (every 4-6 hours) for sustained bronchodilation.
Topically applied; systemic absorption is minimal but can be increased with use on large areas, occlusive dressings, or damaged skin. Absorbed portion is metabolized primarily in the liver via hepatic microsomal enzymes (CYP3A4) and excreted by the kidneys.
Metabolized by catechol-O-methyltransferase (COMT), monoamine oxidase (MAO), and sulfate conjugation in the gastrointestinal tract and liver.
Primarily hepatic metabolism (approximately 95%) followed by renal excretion of inactive metabolites (<5% unchanged). Biliary/fecal excretion is negligible.
Primarily renal excretion of unchanged drug and sulfate conjugates; 60-70% as unchanged drug, 15-20% as sulfate metabolites, minor biliary/fecal elimination (<5%).
Hydrocortisone is approximately 90–95% bound to corticosteroid-binding globulin (CBG, transcortin) and albumin.
50-60% bound to albumin.
Apparent volume of distribution (Vd) is approximately 0.4–0.6 L/kg, indicating moderate tissue distribution and limited penetration into CNS.
4-5 L/kg (large Vd indicating extensive tissue distribution, particularly lung tissue).
Topical: Bioavailability is negligible (<1%) through intact skin; may increase (up to 30%) with damaged skin or occlusive dressings. Rectal: Bioavailability is approximately 10–20% via mucosal absorption, with first-pass metabolism reducing systemic exposure.
Inhalation: 10-20% (due to deposition and first-pass metabolism from swallowed portion). Oral: 40-50% (significant first-pass metabolism to sulfate conjugates).
No adjustment required for topical use; systemic absorption minimal.
No dose adjustment required for GFR ≥30 m L/min; for GFR <30 m L/min, reduce dose by 50% and monitor for systemic effects.
No adjustment required for topical use; hepatic metabolism negligible.
No specific Child-Pugh-based adjustments; caution in severe hepatic impairment due to reduced clearance; consider dose reduction of 50% in Child-Pugh Class C.
Children ≥2 years: Apply a thin film to affected area 2-3 times daily. Use lowest potency preparation; avoid prolonged use.
0.15 mg/kg/dose (max 5 mg) via nebulization every 4-6 hours; or 1-2 inhalations (90 mcg each) via MDI every 4-6 hours as needed.
Use lowest effective dose; monitor for skin atrophy and systemic effects due to thinner skin and increased percutaneous absorption.
Use lowest effective dose; potential for increased cardiovascular sensitivity; consider starting at 1.25 mg nebulization or 1 inhalation every 6 hours, titrate cautiously.
None
Increased risk of asthma-related death with beta-2 agonists; use inhaled beta-2 agonists alone for asthma is not recommended without concomitant inhaled corticosteroid.
Systemic absorption may cause reversible HPA axis suppression,Cushing's syndrome, hyperglycemia, and glucosuria with prolonged use,Local adverse reactions: atrophy, striae, telangiectasias, acneiform eruptions, perioral dermatitis,May mask signs of infection,Use with caution in pediatric patients due to increased susceptibility to HPA axis suppression,Avoid use on face, intertriginous areas, and under occlusive dressings unless directed by physician
Paradoxical bronchospasm, cardiovascular effects (tachycardia, hypertension, arrhythmias), hypokalemia, hyperglycemia, immediate hypersensitivity reactions, and worsening of asthma symptoms.
Hypersensitivity to any component of the formulation,Untreated bacterial, viral, fungal, or parasitic skin infections,Viral skin infections (e.g., herpes simplex, varicella) at treatment site,Perioral dermatitis,Rosacea
Hypersensitivity to beta-2 agonists or any component of the formulation; use in patients with tachyarrhythmias (e.g., atrial fibrillation with rapid ventricular response) unless benefit outweighs risk.
No known food interactions with topical ALA-CORT.
No significant food interactions. Avoid caffeine-containing foods and beverages if experiencing palpitations or tremors. Maintain adequate potassium intake as beta-2 agonists can cause hypokalemia.
FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies show increased risk of cleft palate. Second/third trimester: Risk of intrauterine growth restriction, adrenal suppression in fetus. Avoid prolonged use.
FDA Pregnancy Category C. First trimester: Insufficient human data; animal studies show teratogenicity at high doses. Second/third trimester: Risk of fetal tachycardia, hypoglycemia, and intrauterine growth restriction due to beta-2 receptor stimulation. Prolonged use may delay labor.
Provides small amounts in breast milk; M/P ratio unknown. At maternal doses up to 80 mg/day, no adverse effects reported in infants. Consider risk-benefit with high doses or prolonged therapy.
Excreted into breast milk in low amounts; M/P ratio estimated at 0.8 (range 0.5-1.2). Considered compatible with breastfeeding; monitor infant for signs of stimulation (e.g., tachycardia, irritability).
Pregnancy-induced pharmacokinetic changes (increased clearance, volume of distribution) may require increased dosing, but clinical response should guide adjustment. Avoid high doses and prolonged use.
No routine dose adjustment required. Increased clearance in pregnancy may necessitate higher doses for bronchodilation; monitor clinical response. For tocolysis, use lowest effective dose and limit duration to 48-72 hours due to maternal-fetal risks.
ALA-CORT (hydrocortisone acetate 2.5% and pramoxine HCl 1%) is a topical corticosteroid with anesthetic. Use for short-term relief of pruritus and inflammation in corticosteroid-responsive dermatoses. Avoid prolonged use on intertriginous or occluded areas. Limit to <2 weeks continuous use in adults to avoid skin atrophy. Not recommended for children <2 years.
Beta-2 agonists (e.g., albuterol, salmeterol) are primarily used for bronchodilation in asthma and COPD. Short-acting beta-2 agonists (SABAs) are first-line for acute symptoms, while long-acting beta-2 agonists (LABAs) are maintenance therapy, never as monotherapy in asthma. Monitor for hypokalemia and tachycardia. Use with caution in patients with cardiovascular disease, hyperthyroidism, or diabetes. Inhaled route minimizes systemic effects. Overuse indicates poor disease control.
Apply a thin layer to affected area no more than 3-4 times daily.,Do not cover with bandages or plastic unless directed by doctor.,Avoid contact with eyes, mouth, or broken skin.,Discontinue and notify doctor if infection, irritation, or no improvement after 7 days.,Do not use for diaper dermatitis or under diapers/occlusive dressings.,Keep out of reach of children.
Use only as prescribed; do not increase frequency or dose without consulting your doctor.,Rinse mouth with water after using inhalers containing corticosteroids to prevent thrush.,Seek emergency help if symptoms worsen or if you need more than 2 puffs per week of rescue inhaler.,Know the difference between rescue (blue) and controller (usually brown/purple) inhalers.,Shake inhaler well before use and use proper technique (spacer if needed).,Report palpitations, chest pain, or severe anxiety to your healthcare provider.,Do not stop controller medication suddenly as it may cause worsening of symptoms.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALA-CORT vs BETA-2, answered by our medical review team.
ALA-CORT is a Topical Corticosteroid that works by Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.. BETA-2 is a Beta-2 Agonist that works by Beta-2 adrenergic receptor agonist; stimulates adenylate cyclase, increasing c AMP, leading to bronchodilation and inhibition of mast cell mediator release.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALA-CORT and BETA-2 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALA-CORT is: Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.. The standard adult dose of BETA-2 is: 2.5 mg via nebulization every 4-6 hours as needed for bronchospasm; or 90 mcg (2 inhalations) via metered-dose inhaler every 4-6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALA-CORT and BETA-2 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALA-CORT is classified as Category C. FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies show increased risk of cleft palate. Second/third trimester: Risk of intrauterine growth restri. BETA-2 is classified as Category C. FDA Pregnancy Category C. First trimester: Insufficient human data; animal studies show teratogenicity at high doses. Second/third trimester: Risk of fetal tachycardia, hypoglycemi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.